Table 2

Combined evaluation of serum CEA and CA 15.3 levels in patients with breast adenocarcinoma

Stage% CA 15.3 positiveIncrease in sensitivity by adding CEA
Overall population33.06.0%
Stage IV62.50.0%
Metastatic disease80.82.1%
Local recurrence48.33.4%